Paul Matteis
Stock Analyst at Stifel
(2.34)
# 2,526
Out of 5,180 analysts
129
Total ratings
43.08%
Success rate
-1.41%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals | Maintains: Buy | $35 → $40 | $24.66 | +62.21% | 3 | Mar 27, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $39 → $42 | $20.13 | +108.64% | 2 | Mar 26, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $73 → $77 | $75.09 | +2.54% | 7 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $25 → $24 | $22.26 | +7.82% | 7 | Feb 26, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $445 → $466 | $446.54 | +4.36% | 21 | Feb 13, 2026 | |
| QURE uniQure | Maintains: Buy | $50 → $40 | $16.35 | +144.65% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $131.74 | +42.71% | 11 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $18.13 | +115.11% | 5 | Dec 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $495 → $508 | $330.87 | +53.53% | 16 | Dec 11, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $20.33 | +37.73% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $3 | $1.95 | +53.85% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $73 → $61 | $56.49 | +7.98% | 11 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $144 → $202 | $183.33 | +10.18% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $1.77 | +577.97% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $86.97 | +8.08% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $40.09 | -20.18% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $14.06 | +127.60% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.53 | +98.92% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.15 | +86.05% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $22.48 | -55.52% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $20.16 | +197.62% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $35.36 | +1.81% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $31.29 | +11.86% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $13.06 | +122.05% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.74 | +248.43% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.57 | +1,999.74% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.36 | +1,044.07% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $7.25 | +782.76% | 1 | Feb 21, 2018 |
LB Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $24.66
Upside: +62.21%
KalVista Pharmaceuticals
Mar 26, 2026
Maintains: Buy
Price Target: $39 → $42
Current: $20.13
Upside: +108.64%
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $73 → $77
Current: $75.09
Upside: +2.54%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $25 → $24
Current: $22.26
Upside: +7.82%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Hold
Price Target: $445 → $466
Current: $446.54
Upside: +4.36%
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $16.35
Upside: +144.65%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $131.74
Upside: +42.71%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $18.13
Upside: +115.11%
Alnylam Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $330.87
Upside: +53.53%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $20.33
Upside: +37.73%
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $1.95
Upside: +53.85%
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $56.49
Upside: +7.98%
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $183.33
Upside: +10.18%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $1.77
Upside: +577.97%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $86.97
Upside: +8.08%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $40.09
Upside: -20.18%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $14.06
Upside: +127.60%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $5.53
Upside: +98.92%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.15
Upside: +86.05%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $22.48
Upside: -55.52%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $20.16
Upside: +197.62%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $35.36
Upside: +1.81%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $31.29
Upside: +11.86%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $13.06
Upside: +122.05%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $5.74
Upside: +248.43%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.57
Upside: +1,999.74%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.36
Upside: +1,044.07%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $7.25
Upside: +782.76%